Detalhe da pesquisa
1.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 22(11): 1573-1581, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656225
2.
Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials.
N Engl J Med
; 376(16): 1504-1505, 2017 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28423289
3.
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Clin Cancer Res
; 29(19): 3835-3840, 2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37212825
4.
FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
Gynecol Oncol
; 147(1): 3-10, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844539
5.
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.
J Clin Oncol
; 40(30): 3489-3500, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095296
6.
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Clin Cancer Res
; 28(6): 1058-1071, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711631
7.
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Clin Cancer Res
; 28(6): 1072-1086, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34711632
8.
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
Clin Cancer Res
; 27(9): 2430-2434, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563634
9.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
Clin Cancer Res
; 27(9): 2408-2415, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563637
10.
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement.
Clin Cancer Res
; 27(9): 2394-2399, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563632
11.
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Clin Cancer Res
; 24(17): 4066-4071, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29650751
12.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.
J Clin Oncol
; 35(33): 3774-3780, 2017 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28968173
13.
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement.
J Clin Oncol
; 35(33): 3737-3744, 2017 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28968170
14.
Transforming Clinical Trial Eligibility Criteria to Reflect Practical Clinical Application.
Am Soc Clin Oncol Educ Book
; 35: 83-90, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27249689
15.
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Clin Cancer Res
; 22(18): 4545-9, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27401247
16.
Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions.
Clin Pharmacol Ther
; 108(3): 419-421, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640034
17.
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Clin Cancer Res
; 21(19): 4257-61, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26187614
18.
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
J Thorac Oncol
; 13(6): 748-751, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793646
19.
Successes and Challenges of PARP Inhibitors in Cancer Therapy.
Front Oncol
; 5: 222, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26528434